Please enable JavaScript to continue using this application.

Compare $NVCT vs $PRME | Chartloom

Compare

$NVCT vs $PRME

Nuvectis Pharma Inc · Prime Medicine Inc

NVCT

Nuvectis Pharma Inc

PRME

Prime Medicine Inc

Compare $NVCT vs $PRME

Comparing Nuvectis Pharma Inc and Prime Medicine Inc

NVCTNuvectis Pharma Inc

PRMEPrime Medicine Inc

NVCTNuvectis Pharma Inc

Market cap

$666M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

148.2%

52W performance

239.0%

FCF yield

-2.9%

PRMEPrime Medicine Inc

Market cap

$721M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

126.79x

Rev growth (TTM)

-17.9%

YTD performance

13.0%

52W performance

-38.1%

FCF yield

-21.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NVCT

PRME

Detailed metrics comparison

NVCT

Nuvectis Pharma Inc

PRME

Prime Medicine Inc

Market Cap

NVCT$666M

PRME$721M

Enterprise Value

NVCT$644M

PRME$673M

Price

NVCT$21.12

PRME$3.99

P/E Ratio

NVCTN/A

PRMEN/A

P/S Ratio

NVCT0.00x

PRME176.94x

EV/Sales

NVCT0.00x

PRME165.29x

EV/EBITDA

NVCT0.00x

PRME0.00x

P/B Ratio

NVCT78.79x

PRME13.58x

P/FCF Ratio

NVCTN/A

PRMEN/A

EV/FCF

NVCT-33.00x

PRME-4.29x

PEG Ratio

NVCTN/A

PRMEN/A

Forward P/E (NTM)

NVCTN/A

PRMEN/A

Forward P/S (NTM)

NVCTN/A

PRME126.79x

Revenue (TTM)

NVCT$0

PRME$4M

Revenue Growth (YoY)

NVCTN/A

PRME-17.9%

Forward Rev Growth

NVCT0.0%

PRME22.7%

Gross Margin (TTM)

NVCT0.0%

PRME0.0%

Operating Margin (TTM)

NVCT0.0%

PRME0.0%

EBITDA Margin (TTM)

NVCT0.0%

PRME-4643.3%

Net Margin (TTM)

NVCT0.0%

PRME-4613.1%

FCF Margin (TTM)

NVCTN/A

PRME-3850.9%

Net Income (TTM)

NVCT$-30M

PRME$-188M

FCF (TTM)

NVCT$-20M

PRME$-157M

EPS (TTM)

NVCT-$1.29

PRME-$1.06

ROE (TTM)

NVCT-16947.0%

PRME-18827.0%

ROA (TTM)

NVCT-9680.0%

PRME-5911.0%

ROIC (TTM)

NVCT-16947.0%

PRME-18827.0%

Cash

NVCT$22M

PRME$47M

Debt

NVCT$0

PRME$0

Net Cash/Debt

NVCT$22M

PRME$47M

Current Ratio (TTM)

NVCT1.68x

PRME3.05x

Quick Ratio (TTM)

NVCT1.68x

PRME3.01x

Debt/Equity (TTM)

NVCT0.00x

PRME0.00x

Debt/Assets (TTM)

NVCT0.0%

PRME0.0%

Interest Coverage (TTM)

NVCTN/A

PRMEN/A

Net Debt/EBITDA (TTM)

NVCT0.00x

PRME0.00x

Beta

NVCT-0.23

PRME2.35

52W Performance

NVCT239.0%

PRME-38.1%

YTD Performance

NVCT148.2%

PRME13.0%

% from 52W High

NVCT-27.9%

PRME-40.0%

% from 52W Low

NVCT280.5%

PRME49.4%

Asset Turnover (TTM)

NVCT0.00x

PRME0.01x

FCF Yield (TTM)

NVCT-2.9%

PRME-21.8%

Earnings Yield (TTM)

NVCT-4.5%

PRME-26.1%

Dividend Yield (TTM)

NVCTN/A

PRMEN/A

Rule of 40

NVCT0.0

PRME-3,868.8

EV/GP/RG

NVCTN/A

PRMEN/A

Ticker research

View NVCT research View PRME research

Metric	NVCT Nuvectis Pharma Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$666M	$721M
Enterprise Value	$644M	$673M
Price	$21.12	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	176.94x
EV/Sales	0.00x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	78.79x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.00x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	126.79x
Revenue & Growth
Revenue (TTM)	$0	$4M
Revenue Growth (YoY)	N/A	-17.9%
Forward Rev Growth	0.0%	22.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4643.3%
Net Margin (TTM)	0.0%	-4613.1%
FCF Margin (TTM)	N/A	-3850.9%
Net Income (TTM)	$-30M	$-188M
FCF (TTM)	$-20M	$-157M
EPS (TTM)	-$1.29	-$1.06
ROE (TTM)	-16947.0%	-18827.0%
ROA (TTM)	-9680.0%	-5911.0%
ROIC (TTM)	-16947.0%	-18827.0%
Financial Health
Cash	$22M	$47M
Debt	$0	$0
Net Cash/Debt	$22M	$47M
Current Ratio (TTM)	1.68x	3.05x
Quick Ratio (TTM)	1.68x	3.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.23	2.35
52W Performance	239.0%	-38.1%
YTD Performance	148.2%	13.0%
% from 52W High	-27.9%	-40.0%
% from 52W Low	280.5%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-2.9%	-21.8%
Earnings Yield (TTM)	-4.5%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,868.8
EV/GP/RG	N/A	N/A
Ticker research	View NVCT research	View PRME research

Valuation

P/S Ratio

NVCT

0.00x

PRME

176.94x

EV/FCF

NVCT

-33.00x

PRME

-4.29x

Growth & revenue

Revenue Growth TTM

PRME

-17.9%

Forward Revenue Growth

PRME

22.7%

NVCT

0.0%

Profitability & performance

Gross Margin

NVCT

0.0%

PRME

0.0%

ROE

NVCT

-16947.0%

PRME

-18827.0%

FCF Yield %

NVCT

-2.9%

PRME

-21.8%

52-Week Performance

NVCT

239.0%

PRME

-38.1%

Detailed metrics comparison

NVCT

Nuvectis Pharma Inc

PRME

Prime Medicine Inc

Market Cap

NVCT$666M

PRME$721M

Enterprise Value

NVCT$644M

PRME$673M

Price

NVCT$21.12

PRME$3.99

P/E Ratio

NVCTN/A

PRMEN/A

P/S Ratio

NVCT0.00x

PRME176.94x

EV/Sales

NVCT0.00x

PRME165.29x

EV/EBITDA

NVCT0.00x

PRME0.00x

P/B Ratio

NVCT78.79x

PRME13.58x

P/FCF Ratio

NVCTN/A

PRMEN/A

EV/FCF

NVCT-33.00x

PRME-4.29x

PEG Ratio

NVCTN/A

PRMEN/A

Forward P/E (NTM)

NVCTN/A

PRMEN/A

Forward P/S (NTM)

NVCTN/A

PRME126.79x

Revenue (TTM)

NVCT$0

PRME$4M

Revenue Growth (YoY)

NVCTN/A

PRME-17.9%

Forward Rev Growth

NVCT0.0%

PRME22.7%

Gross Margin (TTM)

NVCT0.0%

PRME0.0%

Operating Margin (TTM)

NVCT0.0%

PRME0.0%

EBITDA Margin (TTM)

NVCT0.0%

PRME-4643.3%

Net Margin (TTM)

NVCT0.0%

PRME-4613.1%

FCF Margin (TTM)

NVCTN/A

PRME-3850.9%

Net Income (TTM)

NVCT$-30M

PRME$-188M

FCF (TTM)

NVCT$-20M

PRME$-157M

EPS (TTM)

NVCT-$1.29

PRME-$1.06

ROE (TTM)

NVCT-16947.0%

PRME-18827.0%

ROA (TTM)

NVCT-9680.0%

PRME-5911.0%

ROIC (TTM)

NVCT-16947.0%

PRME-18827.0%

Cash

NVCT$22M

PRME$47M

Debt

NVCT$0

PRME$0

Net Cash/Debt

NVCT$22M

PRME$47M

Current Ratio (TTM)

NVCT1.68x

PRME3.05x

Quick Ratio (TTM)

NVCT1.68x

PRME3.01x

Debt/Equity (TTM)

NVCT0.00x

PRME0.00x

Debt/Assets (TTM)

NVCT0.0%

PRME0.0%

Interest Coverage (TTM)

NVCTN/A

PRMEN/A

Net Debt/EBITDA (TTM)

NVCT0.00x

PRME0.00x

Beta

NVCT-0.23

PRME2.35

52W Performance

NVCT239.0%

PRME-38.1%

YTD Performance

NVCT148.2%

PRME13.0%

% from 52W High

NVCT-27.9%

PRME-40.0%

% from 52W Low

NVCT280.5%

PRME49.4%

Asset Turnover (TTM)

NVCT0.00x

PRME0.01x

FCF Yield (TTM)

NVCT-2.9%

PRME-21.8%

Earnings Yield (TTM)

NVCT-4.5%

PRME-26.1%

Dividend Yield (TTM)

NVCTN/A

PRMEN/A

Rule of 40

NVCT0.0

PRME-3,868.8

EV/GP/RG

NVCTN/A

PRMEN/A

Ticker research

View NVCT research View PRME research

Metric	NVCT Nuvectis Pharma Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$666M	$721M
Enterprise Value	$644M	$673M
Price	$21.12	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	176.94x
EV/Sales	0.00x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	78.79x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-33.00x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	126.79x
Revenue & Growth
Revenue (TTM)	$0	$4M
Revenue Growth (YoY)	N/A	-17.9%
Forward Rev Growth	0.0%	22.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4643.3%
Net Margin (TTM)	0.0%	-4613.1%
FCF Margin (TTM)	N/A	-3850.9%
Net Income (TTM)	$-30M	$-188M
FCF (TTM)	$-20M	$-157M
EPS (TTM)	-$1.29	-$1.06
ROE (TTM)	-16947.0%	-18827.0%
ROA (TTM)	-9680.0%	-5911.0%
ROIC (TTM)	-16947.0%	-18827.0%
Financial Health
Cash	$22M	$47M
Debt	$0	$0
Net Cash/Debt	$22M	$47M
Current Ratio (TTM)	1.68x	3.05x
Quick Ratio (TTM)	1.68x	3.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.23	2.35
52W Performance	239.0%	-38.1%
YTD Performance	148.2%	13.0%
% from 52W High	-27.9%	-40.0%
% from 52W Low	280.5%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-2.9%	-21.8%
Earnings Yield (TTM)	-4.5%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,868.8
EV/GP/RG	N/A	N/A
Ticker research	View NVCT research	View PRME research